Race Oncology Limited announced that Mr. Daniel (Danny) Sharp has been appointed as an Independent Non-Executive Director. After commencing his career as a solicitor, Mr. Sharp has had an extensive investment banking career of more than 25 years where he has advised the boards of technology and healthcare-based organizations on global capital markets. He has an extensive network of institutional and private wealth investors.

From 2012 to 2020, Mr. Sharp was an Executive Director of leading independent, financial services firm Canaccord Genuity. He is currently a Non-Executive Director of health informatics company, Alcidion Group Limited and Non-Executive Director of the dermatology-focused Botanix Pharmaceuticals Limited. He is also a member of the investment committee of the Baker Heart and Diabetes Institute Foundation.

Mr. Sharp previously headed the corporate banking division of Shaw and Partners and Lodge Partners. He holds a Bachelor of Economics and Law and is a CFA Charter Holder.